David Badesch
Overview
Explore the profile of David Badesch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Preston I, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, Hoeper M, et al.
Eur Respir J
. 2025 Feb;
PMID: 39978862
Background: SOTERIA (NCT04796337) is an ongoing open-label study evaluating long-term safety, tolerability, and efficacy of sotatercept in participants with pulmonary arterial hypertension (PAH). Methods: Eligible adults with PAH on stable...
2.
Winters R, Forbes L, Ivy D, Cool C, Park B, Hountras P, et al.
Respirol Case Rep
. 2024 Nov;
12(11):e70064.
PMID: 39588328
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary vascular disease that is difficult to distinguish clinically from pulmonary arterial hypertension (PAH). Multiple genes have been implicated in disease...
3.
Kovacs G, Bartolome S, Denton C, Gatzoulis M, Gu S, Khanna D, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209475
Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary...
4.
Rockstrom M, Jin Y, Peterson R, Hountras P, Badesch D, Gu S, et al.
Pulm Circ
. 2024 May;
14(2):e12375.
PMID: 38736893
Identification of long-term calcium channel blocker (CCB) responders with acute vasodilator challenge is critical in the evaluation of patients with pulmonary arterial hypertension. Currently there is no standardized approach for...
5.
McCormick A, Krishnan A, Badesch D, Benza R, Bull T, De Marco T, et al.
Heart
. 2023 Feb;
109(14):1098-1105.
PMID: 36787969
Objective: Pulmonary artery compliance (PAC), estimated as stroke volume (SV) divided by pulmonary artery pulse pressure (PP), may be a predictor of survival in pulmonary arterial hypertension (PAH). Resistance-compliance (RC)...
6.
DuBrock H, Burger C, Bartolome S, Feldman J, Ivy D, Rosenzweig E, et al.
Pulm Circ
. 2022 Dec;
12(4):e12172.
PMID: 36540874
[This corrects the article DOI: 10.1177/20458940211020913.].
7.
Hill N, Feldman J, Sahay S, Benza R, Preston I, Badesch D, et al.
Pulm Circ
. 2022 Aug;
12(3):e12119.
PMID: 36034402
The INSPIRE trial was a Phase 3, open-label, multicenter trial (LTI-301) that enrolled patients with pulmonary arterial hypertension (PAH) ≥ 18 years of age who transitioned to Yutrepia from nebulized...
8.
Grinnan D, Kang L, DeWilde C, Badesch D, Benza R, Bull T, et al.
Pulm Circ
. 2022 Aug;
12(3):e12120.
PMID: 35911181
Outcomes of patients with pulmonary arterial hypertension (PAH) may be associated with social determinants of health (SDOH) and other baseline patient characteristics. At present, there is no prognostic model to...
9.
Lee M, Doran J, Bang T, Hohsfield R, Hountras P, Boddie G, et al.
Chest
. 2021 Jul;
160(6):2260-2265.
PMID: 34284002
No abstract available.
10.
DuBrock H, Burger C, Bartolome S, Feldman J, Ivy D, Rosenzweig E, et al.
Pulm Circ
. 2021 Jun;
11(3):20458940211020913.
PMID: 34158918
Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to...